Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus responsible for coronavirus disease 2019 (COVID‐19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin‐converting enzyme 2 (ACE2), which facilitates SARS‐CoV‐2 host cell entry, may be impacted by...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Hypertens (Greenwich)
Autori principali: Cohen, Jordana B., Hanff, Thomas C., Corrales‐Medina, Vicente, William, Preethi, Renna, Nicolas, Rosado‐Santander, Nelson R., Rodriguez‐Mori, Juan E., Spaak, Jonas, Andrade‐Villanueva, Jaime, Chang, Tara I., Barbagelata, Alejandro, Alfonso, Carlos E., Bernales‐Salas, Eduardo, Coacalla, Johanna, Castro‐Callirgos, Carlos Augusto, Tupayachi‐Venero, Karen E., Medina, Carola, Valdivia, Renzo, Villavicencio, Mirko, Vasquez, Charles R., Harhay, Michael O., Chittams, Jesse, Sharkoski, Tiffany, Byrd, James Brian, Edmonston, Daniel L., Sweitzer, Nancy, Chirinos, Julio A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Covid‐19
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722152/
https://ncbi.nlm.nih.gov/pubmed/32937008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.14011
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi